Aprogen Biologics Inc. (KRX: 003060)
South Korea
· Delayed Price · Currency is KRW 703.00
-32.00 (-4.35%)
Dec 19, 2024, 3:30 PM KST
Aprogen Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Other Revenue | 0 | - | - | - | 0 | -0 | Upgrade
|
| Revenue | 68,033 | 87,364 | 65,190 | 56,482 | 53,320 | 50,904 | Upgrade
|
| Revenue Growth (YoY) | -16.77% | 34.01% | 15.42% | 5.93% | 4.75% | 12.13% | Upgrade
|
| Cost of Revenue | 71,660 | 99,337 | 39,380 | 31,607 | 30,515 | 30,911 | Upgrade
|
| Gross Profit | -3,627 | -11,974 | 25,810 | 24,875 | 22,805 | 19,992 | Upgrade
|
| Selling, General & Admin | 27,464 | 29,789 | 28,914 | 25,947 | 23,579 | 21,093 | Upgrade
|
| Research & Development | 23,235 | 15,000 | 2,187 | 1,735 | 697.7 | 336.12 | Upgrade
|
| Other Operating Expenses | 363.36 | 357.6 | 365.27 | 416.95 | 592.21 | 343.19 | Upgrade
|
| Operating Expenses | 73,294 | 58,716 | 30,015 | 28,850 | 23,885 | 21,923 | Upgrade
|
| Operating Income | -76,922 | -70,690 | -4,204 | -3,975 | -1,081 | -1,930 | Upgrade
|
| Interest Expense | -4,350 | -3,668 | -274.41 | -31.14 | -49.06 | -3,325 | Upgrade
|
| Interest & Investment Income | 3,444 | 4,488 | 16,645 | 13,587 | 9,176 | 3,400 | Upgrade
|
| Earnings From Equity Investments | 92,677 | 79,786 | 94.73 | 352.2 | 1,510 | 4,674 | Upgrade
|
| Currency Exchange Gain (Loss) | 193.41 | -6.22 | 33.16 | 12.72 | -26.11 | -15.49 | Upgrade
|
| Other Non Operating Income (Expenses) | -16,129 | 564.26 | 209.78 | 347.85 | 423.69 | 45,486 | Upgrade
|
| EBT Excluding Unusual Items | -1,086 | 10,474 | 12,504 | 10,294 | 9,953 | 48,289 | Upgrade
|
| Gain (Loss) on Sale of Investments | 812.91 | 29,950 | 2,638 | 1,623 | 6,341 | -50,265 | Upgrade
|
| Gain (Loss) on Sale of Assets | -151,526 | -151,537 | 3.1 | 53.08 | 593.48 | 0.89 | Upgrade
|
| Asset Writedown | -2,271 | -2,271 | -264.15 | -2,134 | -241.5 | -553.33 | Upgrade
|
| Other Unusual Items | 4,023 | - | -1.04 | -4.76 | -2.67 | -529.25 | Upgrade
|
| Pretax Income | -150,046 | -113,383 | 14,881 | 9,831 | 16,644 | -3,057 | Upgrade
|
| Income Tax Expense | -1,981 | 1,947 | 1,260 | 679.69 | -2,274 | 409.26 | Upgrade
|
| Earnings From Continuing Operations | -148,065 | -115,330 | 13,621 | 9,151 | 18,918 | -3,467 | Upgrade
|
| Minority Interest in Earnings | 6,292 | -2,940 | -981.32 | -1,048 | -7,665 | -4,848 | Upgrade
|
| Net Income | -141,774 | -118,270 | 12,639 | 8,103 | 11,253 | -8,315 | Upgrade
|
| Net Income to Common | -141,774 | -118,270 | 12,639 | 8,103 | 11,253 | -8,315 | Upgrade
|
| Net Income Growth | - | - | 55.99% | -28.00% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 93 | 63 | 40 | 40 | 32 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 93 | 63 | 40 | 40 | 32 | 16 | Upgrade
|
| Shares Change (YoY) | 62.18% | 56.07% | 1.42% | 25.52% | 94.17% | 66.31% | Upgrade
|
| EPS (Basic) | -1529.21 | -1874.81 | 312.69 | 203.29 | 354.38 | -508.42 | Upgrade
|
| EPS (Diluted) | -1529.21 | -1874.81 | 310.00 | 200.00 | 350.00 | -510.00 | Upgrade
|
| EPS Growth | - | - | 55.00% | -42.86% | - | - | Upgrade
|
| Free Cash Flow | -43,470 | -61,739 | 24,444 | -7,023 | 7,112 | -1,416 | Upgrade
|
| Free Cash Flow Per Share | -468.88 | -978.68 | 604.74 | -176.20 | 223.97 | -86.60 | Upgrade
|
| Gross Margin | -5.33% | -13.71% | 39.59% | 44.04% | 42.77% | 39.27% | Upgrade
|
| Operating Margin | -113.07% | -80.91% | -6.45% | -7.04% | -2.03% | -3.79% | Upgrade
|
| Profit Margin | -208.39% | -135.38% | 19.39% | 14.35% | 21.10% | -16.33% | Upgrade
|
| Free Cash Flow Margin | -63.90% | -70.67% | 37.50% | -12.43% | 13.34% | -2.78% | Upgrade
|
| EBITDA | -57,697 | -49,292 | -1,800 | -1,903 | 851.33 | -269.75 | Upgrade
|
| EBITDA Margin | -84.81% | -56.42% | -2.76% | -3.37% | 1.60% | -0.53% | Upgrade
|
| D&A For EBITDA | 19,225 | 21,398 | 2,404 | 2,072 | 1,932 | 1,661 | Upgrade
|
| EBIT | -76,922 | -70,690 | -4,204 | -3,975 | -1,081 | -1,930 | Upgrade
|
| EBIT Margin | -113.07% | -80.91% | -6.45% | -7.04% | -2.03% | -3.79% | Upgrade
|
| Effective Tax Rate | - | - | 8.47% | 6.91% | - | - | Upgrade
|
| Advertising Expenses | - | 740.04 | 1,371 | 7,800 | 4,343 | 4,462 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.